Canadian breast cancer researchers have opined on the basis of recent studies that the commonly employed chemotherapy drugs may not guarantee the prevention of a relapse.
AC/T, a widely accepted chemotherapy might be ineffective in preventing a relapse as compared to CEF, which has been proven to be more efficient in this regard. A new experimental chemotherapy programme, using EC/T also has been proven to be far superior to AC/T in preventing relapses. The study was based clinical trials involving 2000 women diagnosed with breast cancer, from Canada and U.S, below the age of sixty. All the women had a history of breast surgery prior to chemotherapy. Some of the women were past their menopause. The patients were followed up after almost 2 ½ years from commencement of chemotherapy. 5% extra women ended up with a relapse when on AC/T than when treated with CEF or EC/T.
Canada has developed the CEF regime. Dr. Barbara Whylie, CEO of the Canadian Cancer Society opined that the new clinical trials stand to offer more hope to the affected women ensuring better care and long term survival of the patients. Dr. Margot Burnell who is a breast cancer researcher, pointed out that breast cancer remains as one of the most common cancers diagnosed among women in North America. Almost 40% of all women who are diagnosed with breast cancer are below the age of sixty.